Bicara Therapeutics BCAX Business Segments — G&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's business segments — g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's business segments — G&A?
- Bicara Therapeutics (BCAX) reported business segments — G&A of $12.74M in Q1 2026.
- How has Bicara Therapeutics's business segments — G&A changed year-over-year?
- Bicara Therapeutics's business segments — G&A increased by 70.9% year-over-year, from $7.46M to $12.74M.
- What is the long-term trend for Bicara Therapeutics's business segments — G&A?
- Over 2 years (2023 to 2025), Bicara Therapeutics's business segments — G&A has grown at a 81.4% compound annual growth rate (CAGR), from $9.27M to $30.51M.
- What does business segments — G&A mean?
- The total cost of supporting the administrative, executive, and corporate functions of the organization. This metric provides insight into the company's operational overhead and the efficiency of its corporate management structure.